CoChat

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Open access
Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Borg, Danielle J., Flemming, Nicole B., Harvie, Ben M., Kinneally, Toni L., Yeh, Shang-Ming, McCarthy, Domenica A., Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha, Forbes, Josephine M. · 2016 · Scientific Reports
Cited by 143

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Blood glucose control is the primary strategy to prevent complications in diabetes. At the onset of kidney disease, therapies that inhibit components of the renin angiotensin system (RAS) are also indicated, but these approaches are not wholly effective. Here, we show that once daily administration of the novel glucose lowering agent, empagliflozin, an SGLT2 inhibitor which targets the kidney to block glucose reabsorption, has the potential to improve kidney disease in type 2 diabetes. In male db/db mice, a 10-week treatment with empagliflozin attenuated the diabetes-induced upregulation of profibrotic gene markers, fibronectin and transforming-growth-factor-beta. Other molecular (collagen IV and connective tissue growth factor) and histological (tubulointerstitial total collagen and glomerular collagen IV accumulation) benefits were seen upon dual therapy with metformin. Albuminuria, urinary markers of tubule damage (kidney injury molecule-1, KIM-1 and neutrophil gelatinase-associated lipocalin, NGAL), kidney growth, and glomerulosclerosis, however, were not improved with empagliflozin or metformin, and plasma and intra-renal renin activity was enhanced with empagliflozin. In this model, blood glucose lowering with empagliflozin attenuated some molecular and histological markers of fibrosis but, as per treatment with metformin, did not provide complete renoprotection. Further research to refine the treatment regimen in type 2 diabetes and nephropathy is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep26428

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 143

Metadata

Authors
Gallo, L. A., Ward, M. S., Fotheringham, A. K., Zhuang, A., Borg, D. J., Flemming, N. B., Harvie, B. M., Kinneally, T. L., Yeh, S.-M., McCarthy, D. A., Koepsell, H., Vallon, V., Pollock, C., Panchapakesan, U., & Forbes, J. M.
Venue
Scientific Reports
Published
2016-05-26
Volume
6
Issue
1
Pages
26428-26428
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2403697735
Cited by
143
References
17
FWCI
16.72
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. https://app.cochat.ai/papers/10.1038/srep26428
The paper
Gallo, L. A., Ward, M. S., Fotheringham, A. K., Zhuang, A., Borg, D. J., Flemming, N. B., Harvie, B. M., Kinneally, T. L., Yeh, S.-M., McCarthy, D. A., Koepsell, H., Vallon, V., Pollock, C., Panchapakesan, U., & Forbes, J. M. (2016). Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Scientific Reports. https://doi.org/10.1038/srep26428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.